Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
Clasificación en acciones
#3609
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
Precio por acción
$3.74
Capitalización bursátil
$4.73B
Cambio (1 día)
0.74%
Cambio (1 año)
-51.90%
País
CN
Comercio Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Categoría
Healthcare
Ratio P/B de Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Ratio P/B al October 2026 TTM: 2.70
Según los informes financieros más recientes y el precio de las acciones de Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., el ratio P/B actual (TTM) es 2.70. Al final de 2023, el ratio P/B era 7.46.
Historial del ratio P/B de Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. desde 2013 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 2.70 | -64.57% |
| 2024 | 7.63 | 2.35% |
| 2023 | 7.46 | -18.64% |
| 2022 | 9.16 | -63.42% |
| 2021 | 25.05 | -9.41% |
| 2020 | 27.65 | 962.67% |
| 2019 | 2.60 | -10.83% |
| 2018 | 2.92 | -31.74% |
| 2017 | 4.28 | 0.30% |
| 2016 | 4.26 | -22.48% |
| 2015 | 5.50 | -15.25% |
| 2014 | 6.49 | -31.92% |
| 2013 | 9.53 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | 131.26% |
US
|
|
| 13.2547 | 390.37% |
US
|
|
| 4.208 | 55.68% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 128.72% |
NL
|
